Strona główna・Stock List・Haemonetics Corp

Haemonetics Corp

Closed

SectorHealthcare

90.84 0.63

Buy Sell

Overview

Share price change

24h

Current

Min

89.32

Max

91.22

Key metrics
By Trading Economics
Income	53M 33M
Sales	-7M 339M
P/E Sector Avg	42.456 57.002
EPS	1.14
Profit margin	9.727
Employees	3,009
EBITDA	70M 75M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+4.15% upside

Dividends
By Acuity
Next Earnings	5 lis 2026

Market Stats
By TradingEconomics
Market Cap	-3.8M 3.9B
Previous open	90.21
Previous close	90.84

News Sentiment

By Acuity

95%

4 / 340 Ranking in Healthcare

Haemonetics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 19:51 UTC

Haemonetics Corp shares are higher today, supported by a positive trend in the Health Care Supplies sector and increased trading volume.

13 sie 2026, 19:51 UTC

Haemonetics shares are declining amid rising jobless claims and flat Producer Price Index data, breaking a recent trend of higher daily closes.

12 sie 2026, 20:01 UTC

Haemonetics Corp shares are higher today, supported by unusually high trading volume and a strong upward trajectory since Tuesday's close.

11 sie 2026, 20:06 UTC

Haemonetics Corp shares are higher today, maintaining a position near the upper end of their one-month range despite a minor pullback earlier in the session.

10 sie 2026, 19:46 UTC

Haemonetics Corp shares are declining amid broader market uncertainty following recent U.S. employment data, despite earlier gains during the session.

7 sie 2026, 22:01 UTC

News

Haemonetics shares are lower in after-market trading despite Citigroup raising its price target to $92 and maintaining a Neutral rating.

6 sie 2026, 21:01 UTC

Haemonetics Corp. shares are trading higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

5 sie 2026, 19:31 UTC

Haemonetics Corp shares are lower today, breaking a trend of higher closes. The stock is experiencing unusually high trading volume amid no specific news.

4 sie 2026, 21:01 UTC

Haemonetics Corp shares declined in after-market hours, despite broader market gains from positive U.S.-Iran negotiations and falling crude oil prices.

3 sie 2026, 19:56 UTC

Haemonetics Corp shares are higher, reflecting broader market gains amid positive momentum in major tech stocks and easing geopolitical tensions.

31 lip 2026, 20:04 UTC

Haemonetics Corp shares are higher, with no specific news identified. The broader market has also gained since Thursday's close, recovering from earlier losses.

30 lip 2026, 19:48 UTC

Haemonetics Corp. shares are lower today, continuing a decline since Wednesday. The stock remains above its 20-day moving average despite recent downward movement.

29 lip 2026, 21:21 UTC

Haemonetics Corp shares are lower in after-market trading, reflecting broader declines in the equity market and Health Care Supplies sector amid rising oil prices.

28 lip 2026, 21:01 UTC

Haemonetics Corp shares are lower in after-market hours, following a broader market decline amid a significant drop in the Nikkei 225 Index.

27 lip 2026, 22:51 UTC

Haemonetics Corp shares are higher in after-market trading, supported by falling crude oil prices and strong performance above the 20-day moving average.

24 lip 2026, 20:31 UTC

Haemonetics Corp shares are lower in after-market hours, continuing a decline from Friday's close. No specific news was identified to explain the movement.

23 lip 2026, 23:21 UTC

Haemonetics Corp shares are lower in after-market trading, continuing a decline that began after Thursday's close, reaching the midpoint of their one-month trading range.

22 lip 2026, 20:13 UTC

Shares of Haemonetics Corp are trading higher in after-market hours, positioned above its 20-day moving average amid broader market volatility and rising crude oil prices.

20 lip 2026, 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Peer Comparison

Price change

Haemonetics Corp Forecast

Price Target

By TipRanks

4.15% upside

12 Months Forecast

Average 94.13 USD 4.15%

High 105 USD

Low 84 USD

Based on 9 Wall Street analysts offering 12 month price targets forHaemonetics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Haemonetics Corp - Dist in the past 3 months.

Sentiment

By Acuity

4 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.